Skip to main content
. Author manuscript; available in PMC: 2017 Aug 30.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2016 Jun 14;96(2):406–413. doi: 10.1016/j.ijrobp.2016.06.006

Fig. 1.

Fig. 1

Overall survival by gene alteration. The unknown group included 177 patients who had a negative test result for EGFR or ALK but were not tested for both. With the use of multiple Cox regression to adjust for Lung-GPA prognosis, year of BM, and smoking history, ALK+ (P<.0001) and EGFR+ (P=.001) patients had longer overall survival than did EGFR/ALK− patients. KRAS+ was not significantly different (P=.45) from EGFR/ALK−. Abbreviations: ALK = anaplastic lymphoma kinase; BM = brain metastases; EFGR = epidermal growth factor receptor; KRAS = Kirsten RNA–associated sarcoma; MST = median survival time.